To enable a near real-time method for testing ctDNA, our study employed a tumor-agnostic approach for CTNNB1 ctDNA detection in which the LoD was determined from the HepG2 variant without patient-specific variant optimizations. Here, CTNNB1 is linked to neoplasm.